VistaGen Therapeutics logo

VistaGen TherapeuticsNASDAQ: VTGN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 June 2011

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$83.87 M
-83%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector
-94%vs. 3y high
36%vs. sector
-75%vs. 3y high
93%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:01:53 GMT
$3.10$0.00(0.00%)

Dividend

No data over the past 3 years
$84.00 K$220.00 K
$84.00 K-$10.73 M

Analysts recommendations

Institutional Ownership

VTGN Latest News

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
businesswire.com01 November 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update.

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder
seekingalpha.com15 October 2024 Sentiment: POSITIVE

Vistagen's fasedienol nasal spray is in two phase 3 trials for social anxiety disorder, with results expected in 2025. Positive results from PALISADE-2 were seen previously, and VTGN may need only one of the two studies, PALISADE-3 and PALISADE-4, to succeed in supporting a filing for marketing approval. VTGN had $108.4M as of June 30, 2024, but increased R&D expenses may accelerate cash burn, and the Company could look to use its at-the-market facility or conduct an offering.

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
zacks.com11 October 2024 Sentiment: POSITIVE

VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
zacks.com06 September 2024 Sentiment: POSITIVE

VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript
seekingalpha.com13 August 2024 Sentiment: NEUTRAL

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Madison Elsaadi - B. Riley Securities Operator Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics Fiscal Year 2025 First Quarter Corporate Update Conference Call.

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
zacks.com13 August 2024 Sentiment: NEUTRAL

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.94 per share a year ago.

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
businesswire.com11 June 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update. “Vistagen's fiscal 2024 proved to be a year full of remarkable accomplishments. Most notably, with.

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
businesswire.com07 June 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update. Event: Vistagen Fis.

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
businesswire.com23 May 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and itruvone, its investigational pherine candidate in Phase 2.

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Business Wire09 April 2024 Sentiment: NEGATIVE

Vistagen (Nasdaq: VTGN), a biopharmaceutical company focused on neuroscience, will be presenting posters on clinical trial data for fasedienol and PH80 at an upcoming event.

  • 1(current)

What type of business is VistaGen Therapeutics?

Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

What sector is VistaGen Therapeutics in?

VistaGen Therapeutics is in the Healthcare sector

What industry is VistaGen Therapeutics in?

VistaGen Therapeutics is in the Biotechnology industry

What country is VistaGen Therapeutics from?

VistaGen Therapeutics is headquartered in United States

When did VistaGen Therapeutics go public?

VistaGen Therapeutics initial public offering (IPO) was on 21 June 2011

What is VistaGen Therapeutics website?

https://www.vistagen.com

Is VistaGen Therapeutics in the S&P 500?

No, VistaGen Therapeutics is not included in the S&P 500 index

Is VistaGen Therapeutics in the NASDAQ 100?

No, VistaGen Therapeutics is not included in the NASDAQ 100 index

Is VistaGen Therapeutics in the Dow Jones?

No, VistaGen Therapeutics is not included in the Dow Jones index

When was VistaGen Therapeutics the previous earnings report?

No data

When does VistaGen Therapeutics earnings report?

The next expected earnings date for VistaGen Therapeutics is 08 November 2024